Regulus Therapeutics Inc (Nasdaq:RGLS) stated on Friday that Timothy Wright has stepped down as its chief research and development officer with immediate effect.
Dr Wright has submitted his resignation to the company for personal reasons to pursue a new opportunity.
However, Dr Wright will continue to support the company as its scientific advisor, will enable a smooth transition as well as support its interactions with us FDA regarding RGLS4326, a novel oligonucleotide designed to inhibit miR-17 and designed to preferentially target the kidney.
With corporate headquarters in La Jolla, CA, the biopharmaceutical company is focused on the discovery and development of innovative medicines targeting microRNAs.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial